Venetoclax is a BCL2-specific inhibitor whose use is expanding in hematologic malignancies.20,21 However, blood cancer cells frequently engage distinct mechanisms that can maintain survival following BCL2 inhibition. Here, BCL2 is linked to hematologic disorder.